THURSDAY 5 JULY

08:25

Crombie and Kings Hall residents - bus to AECC

Contemporary issues in therapeutics of bone

Chairs: Richard Eastell (Sheffield, UK) and Nick Harvey (Southampton, UK)

09:00

IS13

Role of bisphosphonates in cancer management
Robert Coleman (Sheffield, UK)

09:30

IS14

Bisphosphonates in the management of Paget’s disease
Stuart Ralston (Edinburgh, UK)

10:00

IS15

Therapeutic options after bisphosphonates
Graham Russell (Oxford, UK) 

10:30

Coffee

11:00

Oral communications 5

Chairs: Mark Cooper (Birmingham, UK) and Graham Russell (Oxford, UK)

11:00

OC23

Height loss predicts fractures in middle aged and older men and women: the EPIC-Norfolk prospective population study
A Moayyeri*^[1], RN Luben^[1], S Bingham^[2], A Welch^[1], NJ Wareham^[3], KT Khaw^[1]
[1]Department of Public Health and Primary Care, Institute of Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK;^[2]MRC Dunn Human Nutrition Unit , Cambridge, UK;^[3]MRC Epidemiology Unit, Cambridge, UK

11:12

OC24

Autologous conditioned serum (ACS) compared to hyaluronan and saline-injections for the treatment of knee osteoarthritis
C Moser*^[1,2], AWA Baltzer^[2], R Krauspe^[1], P Wehling ^[2]
[1]Department of Orthopaedics,Heinrich Heine University Hospital Duesseldorf, Germany;^[2]Centre for Molecular Orthopaedics, Königsallee 53-55, Duesseldorf, Germany

11:24

OC25

An international multicenter randomized comparison of balloon kyphoplasty and nonsurgical care in patients with acute vertebral body compression fractures
D Wardlaw*^[1], S Boonen^[2], L Bastian^[3], J Van Meirhaeghe^[4], AZ St Jan^[4]
[1]Department of Orthopaedics, Woodend Hospital, Eday Road, Aberdeen, UK;^[2]UZ Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium;^[3]Medizinische Hochschule Hannover, Unfallchirurgie, Carl Neuberg Str. 1, 30625 Hannover, Germany;^[4]Dept Orhopaedics, Ruddershove 10, 8000 Brugge, Belgium

11:36

OC26

Muscle function and the effects of hypovitaminosis D in post-menarchal females
KA Ward*^[1], G Das^[2], JL Berry^[1], SA Roberts^[1], R Rawer^[3], JE Adams^[1], MZ Mughal^[4]
[1]University of Manchester, Manchester, UK;^[2]Central Manchester Primary Care Trust, Manchester, UK;^[3]Novotec Medical, Manchester, UK;^[4]Central Manchester & Manchester Childrens University Hospitals NHS Trust, Manchester, UK

11:48

OC27

Effect of the dual-specific Src/Abl kinase inhibitor AZD0530 on bone turnover in patients with advanced solid malignancies
RA Hannon*^[1], G Clack^[2], RB Iacona^[3], P Baker^[2], M Rimmer^[2], F Gossiel^[1], IC Smith^[2], A Robinson ^[2], R Eastell^[1]
[1]Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK;^[2]AstraZeneca, Alderley Park, Macclesfield, UK;^[3]AstraZeneca, Wilmington, Delaware, USA

12:00

Clinical cases

Chairs: Piet Geusens (Maastricht, Netherlands) and Stuart Ralston (Edinburgh, UK)

12:00

CC1

Severe high turnover osteoporosis of unknown cause in a young man with autoimmune hypothyroidism ; a novel syndrome?
PL Riches*, E McRorie, SH Ralston
Centre for Rheumatic Diseases, Western General Hospital, Edinburgh, UK

12:15

CC2

Residual (Ghost) sockets in intravenous bisphosphonate use - evidence of poor healing and slow bone turnover
K Shetty*, J Buoquot
University of Texas Health Science Center, Houston, US

12:30

CC3

Bone pain from chronic sclerosing osteomyelitis successfully treated with risedronate
SE Green*^[1], RW Keen^[2]
[1] Rheumatology Department, Ysbyty Gwynedd, Bangor, Gwynedd, LL57 2PW, UK;^[2]Royal National Orthopaedic Hospital, Stanmore, Middlesex, HA7 4LP, UK

12:45

CC4

Osteoclast activity in childhood acute lymphoblastic leukaemia (ALL) during the first year of treatment
RM Cox^[1], JW Gregory^[1], JH Davies^[2], MEM Jenney^[3], WD Fraser^[4], BAJ Evans*^[1]
[1]Department of Child Health, School of Medicine, Cardiff University, Cardiff, UK;^[2]Southampton University Hospital NHS Trust, Southampton, UK;^[3]Paediatric Oncology, University Hospital of Wales, Cardiff, UK;^[4]Clinical Chemistry, University of Liverpool, Liverpool, UK

13:00

Lunch

13:30

BRS AGM

Bone and Rheumatoid Arthritis

Chairs: Barry Bresnihan (Dublin, Ireland) and David Reid (Aberdeen, UK)

Generously supported by an unrestricted educational grant from Amgen

14:00

Assessment of bone loss in the prediction of long-term disease activity in rheumatoid arthritis
Paul Emery (Leeds, UK)

14:30

Role of RANK/RANKL pathway in the bone loss of rheumatoid arthritis
Kurt Redlich (Vienna, Austria)

15:00

Potential for RANKL inhibition in the management of rheumatoid arthritis
Piet Geusens (Maastricht, Netherlands)

15:30

Close

15:40

Buses from AECC to Aberdeen Airport